Live data · NADAC + Part D CY24 · reviewed daily

Elbasvir and Grazoprevir (ZEPATIER)

First FDA approval2016-01-28
Generic availableNo (brand-only)
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
—/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
—
Across all dosage forms in distribution.
Highest NADAC
—
Range is tight.
Plans with PA
11 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema7 entries indexed · 4 visible
What is Elbasvir and Grazoprevir used for?

Elbasvir and Grazoprevir is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Elbasvir and Grazoprevir?

No. Elbasvir and Grazoprevir is brand-only with no generic equivalents currently in market.

How much does my plan pay for Elbasvir and Grazoprevir?

NADAC pricing data not currently available for this drug.

Is Elbasvir and Grazoprevir on the FDA shortage list?

Elbasvir and Grazoprevir has been discontinued by its manufacturer(s).

3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.